Cytokind

Founded in 2018 and based in San Diego, Cytokind is pivoting from its initial cell therapy focus to commercialize prescription NB-UVB light therapy devices for home-based treatment of autoimmune and inflammatory conditions. The company positions its technology as a non-pharmacologic intervention to calm systemic inflammation, supported by translational research in areas like MS fatigue and post-COVID recovery. Led by a team with medical device and biotech experience, Cytokind operates a direct-to-patient model requiring a physician's prescription, aiming to expand the application of a well-established dermatological treatment into broader immunology.

Prescription Narrowband Ultraviolet B (NB-UVB) phototherapy devices for home use, leveraging specific light wavelengths to modulate systemic inflammation and immune response.

Faces competition from established pharmaceutical therapies for autoimmune diseases and from other medical device companies offering in-clinic and home phototherapy units for dermatology. Differentiation hinges on the systemic immunology hypothesis and the physician-integrated, prescription support model.